Actively Recruiting
Immune Modulation by Exosomes in COVID-19
Led by University of Ulm · Updated on 2024-01-17
40
Participants Needed
1
Research Sites
262 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
CONDITIONS
Official Title
Immune Modulation by Exosomes in COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Critically ill COVID-19 patients with lung dysfunction
- COVID-19 WHO severity degree greater than or equal to 4 or ARDS as defined by WHO on March 13, 2020
- Body weight greater than 50 kg
- Ability to provide informed consent
You will not qualify if you...
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine
Ulm, Germany, 89070
Actively Recruiting
Research Team
M
Manfred Weiss, MD
CONTACT
M
Marion Schneider, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here